extra extra long F22 Conference Banner

The Consortium of Independent Immunology Clinics is grateful for the support from our corporate partners who are committed to improving the lives of patients around the world. It is the generosity of these sponsors that allows the CIIC and its members the opportunity to continue to participate in research that benefits PIDD patients.


ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing, and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.
With three FDA-licensed approved products, including ASCENIV™ (Immune Globulin Intravenous, Human – slra), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (Hepatitis B Immune Globulin, Human), ADMA’s mission is to continue to successfully develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.


CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions, such as coagulation disorders, primary immune deficiencies, hereditary angioedema and respiratory disease.

CuraScript SD provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.


Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world.
We produce essential plasma medicines for patients to treat chronic, rare and, at times, life-threatening conditions. The company provides a comprehensive portfolio of solutions in transfusion medicine and also offers hospitals, pharmacies and healthcare professionals information and services that deliver efficient, expert medical care.
Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership in the industry. For more information, please visit


Octapharma USA is a subsidiary of Octapharma AG, a global human protein products manufacturer. The company is dedicated to the research and manufacture of human proteins and has been committed to patient care and medical innovation for more than 30 years. Its core business is the development, production and sale of human proteins from human plasma and human cell-lines. Patients are treated with Octapharma products in the therapeutic areas of hematology, immunotherapy, and critical care. Octapharma USA is headquartered in Paramus, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit


X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies that modulate the CXCR4 pathway. Leveraging its unparalleled expertise in diseases of the immune system and CXCR4 biology, the company focuses on delivering innovative treatments to people with rare diseases and limited treatment options, including those with certain immunodeficiencies. X4 is solely focused on developing its lead candidate, mavorixafor, for chronic neutropenic disorders including the combined primary immunodeficiency, WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome. For more info: